Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
株価
$0.1559364
最終同期: 2026-09-18
時価総額
$195.17K
変化(1日)
6.60%
変化(1年)
-30.91%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の発行済株式数
September 2025 時点の発行済株式数 113.21M
Fusion Antibodies plc の最新の財務報告および株価によると、現在の発行済株式数は 113.21M です。March 2024 の終わりには、同社は 55.56M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Fusion Antibodies plc(FAB)の発行済株式数の履歴(2013 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 113.21M 18.07%
2025 95.88M 72.58%
2024 55.56M 113.55%
2023 26.01M 0.27%
2022 25.95M 1.91%
2021 25.46M 15.24%
2020 22.09M 0.00%
2019 22.09M 37.07%
2018 16.12M -27.04%
2017 22.09M 0.00%
2016 22.09M 0.00%
2015 22.09M 0.00%
2014 22.09M 0.00%
2013 22.09M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 124.27%
US
62.19M -45.07%
NL
396.00M 249.79%
US
478.91M 323.03%
AU
- -
CH